Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
In the Literature
Finasteride Does Not Affect Survival Rates in Prostate Cancer
In the Literature
September 2013, Vol 4, No 7
Widespread adoption of prostate- specific antigen (PSA) screening has been associated with a 44% reduction in prostate cancer mortality. Although early detection of prostate cancer with PSA testing may lead to reduced mortality, it also leads to significant overdetection of cancer.
Read Article
Combination Therapy with Nivolumab and Ipilimumab Superior to Monotherapy in Advanced Melanoma
In the Literature
July 2013, Vol 4, No 6
A new study investigated whether combined immune blockade with ipilimumab and nivolumab would increase survival in patients with advanced melanoma (Wolchok JD, et al.
N Engl J Med
. 2013;369:122-133).
Read Article
Neoadjuvant Lapatinib and Trastuzumab with Hormonal Therapy for HER2 Breast Cancer
In the Literature
July 2013, Vol 4, No 6
A new phase 2 clinical trial is one of the first to investigate the use of hormonal therapy without chemotherapy as a neoadjuvant strategy for patients with HER2-positive breast cancer (Rimawi MF, et al.
J Clin Oncol
. 2013;31:1726-1731).
Read Article
Prostate Cancer Risk Doubles in Men with Lynch Syndrome
In the Literature
June 2013, Vol 4, No 5
Lynch syndrome (LS) is an inherited syndrome of predisposition to cancer with an increased risk for colorectal cancer ranging from 30% to 80%. Prostate cancer has been described as a component tumor of LS, but the lifetime risk of prostate cancer in patients with LS has not been quantified because of inherent difficulties. In a new analysis, researchers have used genetic data to define the risk of prostate cancer in men with LS (Raymond VM, et al.
J Clin Oncol
. 2013;31:1713-1718).
Read Article
Crizotinib Superior to Standard Chemotherapy in Patients with ALK-Positive Lung Cancer
In the Literature
June 2013, Vol 4, No 5
Read Article
Rituximab Maintenance Prolongs PFS in Patients with Relapsed Lymphoma
In the Literature
June 2013, Vol 4, No 5
Read Article
Many Patients Unwilling to Let Costs Influence the Treatment They Receive
In the Literature
May 2013, Vol 4, No 4
Involving patients in the cost discussion has been suggested as a way to begin to curb the rising costs of care. A new study investigated the inclination of Americans with health insurance to discuss their willingness to have cost as part of the decision-making in their care (Sommers R, et al.
Health Aff [Millwood]
. 2013;32:338-346).
Read Article
Only 57% of Specialty Societies Consider Costs in Clinical Recommendations
In the Literature
May 2013, Vol 4, No 4
Concerns for the cost implications of clinical decision-making by providers and health plans have increased significantly in the recent past, as well as the advice to consider cost in addition to efficacy as a part of the treatment paradigm.
Read Article
Charting the Landscape of Driver Mutations in Acute Myeloid Leukemia
In the Literature
May 2013, Vol 4, No 4
The role of acute myeloid leukemia (AML) mutations in the pathogenesis of the disease has not been fully understood, and many genomic mutations in AML remain unknown. A team of researchers has recently analyzed large databases of genetic mutations and has selected 200 adult cases of de novo AML for their new study, using a variety of methods of genomic sequencing (The Cancer Genome Atlas Research Network.
N Engl J Med
. 2013 May 1. [Epub ahead of print]).
Read Article
Abiraterone versus Placebo before Chemotherapy for Patients with Metastatic Prostate Cancer
In the Literature
January 2013, Vol 4, No 1
A recent study compared the benefit of abiraterone acetate (Zytiga) with prednisone versus placebo plus prednisone for patients with mCRPC before chemotherapy (Ryan CJ, et al.
N Engl J Med
. 2013;368:138-148).
Read Article
Page 8 of 13
3
4
5
6
7
8
9
10
11
12
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma